Spotlight
Clinical
CME/CE
Prostate cancer disparities have deepened since USPSTF negative screening recommendation
“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.
In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minority populations at screening.
At the 2022 AUA Annual Meeting, Pathak shared the abstract, “Racial and ethnic disparities magnified after USPSTF category D recommendation for PSA screening.”
Related Videos
Related Content
